Balsega J. et al., evaluated 724 patients in the BOLERO (Breast Cancer Trial of Oral Everolimus)-2 study, assessing the effects of everolimus and exemestane (an aromatase inhibitor) in postmenopausal women with advanced stages of hormone positive receptor breast cancer. Here, CYP19A1 is linked to breast cancer.